$579 Million is the total value of Octagon Capital Advisors LP's 35 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AMAM | Exit | AMBRX BIOPHARMA INCsponsored ads | $0 | – | -122,800 | -100.0% | -0.09% | – |
IMAB | Exit | I MABsponsored ads | $0 | – | -199,876 | -100.0% | -0.60% | – |
RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -80,000 | -100.0% | -0.60% | – |
KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -152,249 | -100.0% | -1.12% | – |
ARVN | Exit | ARVINAS INC | $0 | – | -178,500 | -100.0% | -2.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-06 |
SC 13G/A | 2024-02-05 |
SC 13G | 2024-02-05 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
SC 13G | 2023-01-25 |
13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.